Loading
Life sciences · Journal article
Cvir Oncology · September 28, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Abstract Yttrium-90 ( 90 Y) radioembolization has evolved into a guideline-endorsed liver-directed therapy with curative, bridging, downstaging, and palliative applications in selected patients with hepatocellular carcinoma (HCC) and liver-dominant malignancies. Advances in selective delivery, personalized dosimetry, and post-treatment imaging have improved efficacy and reproducibility. However, the success of a 90 Y radioembolization program depends on more than technical capability; it depends on whether the institution can deliver it safely, consistently, and in alignment with multidisciplinary goals. Establishing a durable practice requires multidisciplinary alignment, standardized workflows, meaningful quality metrics, leadership support, and patient-centered communication supported by dedicated care coordination. This paper provides a practical framework for building and sustaining a high-performing 90 Y radioembolization program across diverse practice environments, while emphasizing balanced treatment selection within the broader liver cancer armamentarium.